Zydus Lifesciences gets USFDA nod for 2 generic drugs

The tentative approval granted by the US Food and Drug Administration (USFDA) to the company's arm Zydus Worldwide DMCC to market Valbenazine capsules is for strengths 40 mg, 60 mg, and 80 mg, Zydus Lifesciences said in a regulatory filing. As per IQVIA MAT August 2022 data, Valbenazine capsules had annual sales of USD 781 million in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4lJULdx
via IFTTT